Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise

Dow Jones

2025/11/18

By Kelly Cloonan

Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.

The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.

Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.

The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.

Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 17, 2025 16:20 ET (21:20 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584267461"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584267461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584267461?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584267461","market":"sh","top_or_hot":-1,"title":"Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals 4Q Loss Narrows as Sales of Hepatitis C Treatment Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-18 05:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n</p>\n<p>\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n</p>\n<p>\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n</p>\n<p>\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n</p>\n<p>\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 16:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENTA","symbol_name":"Enanta Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584267461","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584267461","pubTimestamp":1763414400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share.Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million.The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication.Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"随着丙型肝炎治疗药物销售额的上升，Enanta Pharmaceuticals第四季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment. \n\n\n  The biotechnology company on Monday posted a loss of $18.7 million, or 87 cents a share, compared with a loss of $28.8 million, or $1.36 a share, a year earlier. Analysts polled by FactSet expected a loss of $1.03 a share. \n\n\n  Revenue rose to $15.1 million compared with $14.6 million a year ago. Analysts projected $16 million. \n\n\n  The growth was driven by increased sales for AbbVie's hepatitis C virus treatment Mavyret, the company said. Enanta derives royalty revenue from sales of the medication. \n\n\n  Enanta said it projects having enough money to fund its existing business and development programs into fiscal 2029. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 16:20 ET (21:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}